Cargando…

A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy

BACKGROUND: The smoothened (SMO) receptor is an essential component of the Sonic hedgehog (SHH) signalling, which is associated with the development of skin basal cell carcinoma (BCC). SMO inhibitors are indicated for BCC patients when surgical treatment or radiation therapy are not possible. Unfort...

Descripción completa

Detalles Bibliográficos
Autores principales: Buetti-Dinh, Antoine, Jensen, Rebecca, Friedman, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960207/
https://www.ncbi.nlm.nih.gov/pubmed/29776351
http://dx.doi.org/10.1186/s12885-018-4451-1
_version_ 1783324549240061952
author Buetti-Dinh, Antoine
Jensen, Rebecca
Friedman, Ran
author_facet Buetti-Dinh, Antoine
Jensen, Rebecca
Friedman, Ran
author_sort Buetti-Dinh, Antoine
collection PubMed
description BACKGROUND: The smoothened (SMO) receptor is an essential component of the Sonic hedgehog (SHH) signalling, which is associated with the development of skin basal cell carcinoma (BCC). SMO inhibitors are indicated for BCC patients when surgical treatment or radiation therapy are not possible. Unfortunately, SMO inhibitors are not always well tolerated due to severe side effects, and their therapeutical success is limited by resistance mutations. METHODS: We investigated how common are resistance-causing mutations in two genomic databases which are not linked to BCC or other cancers, namely 1000 Genomes and ExAC. To examine the potential for combination therapy or other treatments, we further performed knowledge-based simulations of SHH signalling, in the presence or absence of SMO and PI3K/Akt inhibitors. RESULTS: The database analysis revealed that of 18 known mutations associated with Vismodegib-resistance, three were identified in the databases. Treatment of individuals carrying such mutations is thus liable to fail a priori. Analysis of the simulations suggested that a combined inhibition of SMO and the PI3K/Akt signalling pathway may provide an effective reduction in tumour proliferation. However, the inhibition dosage of SMO and PI3K/Akt depended on the activity of phosphodiesterases (PDEs). Under high PDEs activities, SMO became the most important control node of the network. By applying PDEs inhibition, the control potential of SMO decreased and PI3K appeared as a significant factor in controlling tumour proliferation. CONCLUSIONS: Our systems biology approach employs knowledge-based computer simulations to help interpret the large amount of data available in public databases, and provides application-oriented solutions for improved cancer resistance treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4451-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5960207
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59602072018-05-24 A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy Buetti-Dinh, Antoine Jensen, Rebecca Friedman, Ran BMC Cancer Research Article BACKGROUND: The smoothened (SMO) receptor is an essential component of the Sonic hedgehog (SHH) signalling, which is associated with the development of skin basal cell carcinoma (BCC). SMO inhibitors are indicated for BCC patients when surgical treatment or radiation therapy are not possible. Unfortunately, SMO inhibitors are not always well tolerated due to severe side effects, and their therapeutical success is limited by resistance mutations. METHODS: We investigated how common are resistance-causing mutations in two genomic databases which are not linked to BCC or other cancers, namely 1000 Genomes and ExAC. To examine the potential for combination therapy or other treatments, we further performed knowledge-based simulations of SHH signalling, in the presence or absence of SMO and PI3K/Akt inhibitors. RESULTS: The database analysis revealed that of 18 known mutations associated with Vismodegib-resistance, three were identified in the databases. Treatment of individuals carrying such mutations is thus liable to fail a priori. Analysis of the simulations suggested that a combined inhibition of SMO and the PI3K/Akt signalling pathway may provide an effective reduction in tumour proliferation. However, the inhibition dosage of SMO and PI3K/Akt depended on the activity of phosphodiesterases (PDEs). Under high PDEs activities, SMO became the most important control node of the network. By applying PDEs inhibition, the control potential of SMO decreased and PI3K appeared as a significant factor in controlling tumour proliferation. CONCLUSIONS: Our systems biology approach employs knowledge-based computer simulations to help interpret the large amount of data available in public databases, and provides application-oriented solutions for improved cancer resistance treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4451-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-18 /pmc/articles/PMC5960207/ /pubmed/29776351 http://dx.doi.org/10.1186/s12885-018-4451-1 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Buetti-Dinh, Antoine
Jensen, Rebecca
Friedman, Ran
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
title A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
title_full A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
title_fullStr A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
title_full_unstemmed A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
title_short A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
title_sort computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960207/
https://www.ncbi.nlm.nih.gov/pubmed/29776351
http://dx.doi.org/10.1186/s12885-018-4451-1
work_keys_str_mv AT buettidinhantoine acomputationalstudyofhedgehogsignallinginvolvedinbasalcellcarcinomarevealsthepotentialandlimitationofcombinationtherapy
AT jensenrebecca acomputationalstudyofhedgehogsignallinginvolvedinbasalcellcarcinomarevealsthepotentialandlimitationofcombinationtherapy
AT friedmanran acomputationalstudyofhedgehogsignallinginvolvedinbasalcellcarcinomarevealsthepotentialandlimitationofcombinationtherapy
AT buettidinhantoine computationalstudyofhedgehogsignallinginvolvedinbasalcellcarcinomarevealsthepotentialandlimitationofcombinationtherapy
AT jensenrebecca computationalstudyofhedgehogsignallinginvolvedinbasalcellcarcinomarevealsthepotentialandlimitationofcombinationtherapy
AT friedmanran computationalstudyofhedgehogsignallinginvolvedinbasalcellcarcinomarevealsthepotentialandlimitationofcombinationtherapy